SUPPLEMENTATION OF Α-LIPOIC ACID IN DIABETIC PERIPHERAL NEUROPATHY: A PROSPECTIVE OPEN LABEL RANDOMIZED CONTROLLED TRIAL
Keywords:
Nil, Diabeticperipheral neuropathy, Nerveconduction, GlycaemiccontrolAbstract
Abstract Objective: Diabetic peripheral neuropathy is the most common long term complications associated with reduced nerve conduction and blood flow. The present study was designed to investigate the effect of oral supplementation of α-lipoic acid (600 mg/day) on peripheral, sensory and motor nerve conduction and glycaemic control in type 2 diabetes mellitus with peripheral neuropathy. Methods: A total of 20 patients were enrolled in this study, then randomly allocated to two groups control (n=10) and intervention group (n=10). Patients in control group received only oral hypoglycaemic treatment and in intervention group received α-lipoic acid (600 mg/day) oral supplementation along with their oral hypoglycaemic treatment for a period of 3 months. Nerve conduction and glycaemic control were measured at the base line and at the end of 3 months by using specific methods. Results: In intervention group α-lipoic acid supplementation significantly improves 6 of 15 electrophysiological parameters of nerve conduction. Distal latency of peroneal (mean ± SD 5.13 ± 0.52 vs 4.92±0.55; p<0.02), median (mean ± SD 3.66 ± 0.76 vs 3.53±0.63; p<0.03) & ulnar motor nerves (mean ± SD 2.91 ± 0.32 vs 2.82±0.36; p<0.01), and Nerve Conduction Velocity of peroneal (mean ± SD 42.0 ± 3.07 vs 43.4±2.13; p<0.03), median (mean ± SD 51.4 ± 3.31 vs 52.2±3.59; p<0.01) & ulnar motor nerves (mean ± SD 51.0 ± 5.84 vs 52.1±5.46; p<0.03) shows significant improvement. Conclusion: Oral supplementation of α-lipoic acid was found to be effective in improving motor nerve conduction of upper and lower extremities in patients with diabetic peripheral neuropathy.
Downloads
References
Vincent, AM, Russell JW, Low P and Feldman EL Oxidative stress in the pathogenesis of diabetic neuropathy. Endocrin Rev 2004; 26: 612 -628
Ahmed, N Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Pract 2005; 67: 3-21.
Boulton AJ The diabetic foot: From art to science. The 18th Camillo Golgi lecture. Diabetologia, 2004; 47: 1343-1353.
Boulton AJ, Vinik, AI Arezzo JC, Bril V and Feldman EL et al.. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
Mabin, D, Darragon, T, Menez JF, Le Mevez JC and Bercovici, JP Influence of glycemic control on peripheral nerve conduction in insulin-dependent diabetic subjects. Rev. Electroencephalogr. Neurophysiol. Clin., 198212: 75-78.
Pfeifer, MA, Weinberg CR, Cook DL, Reenan A, Halter JR, Ensinck JW and Porte Jr. D, Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care 1984; 7: 447-453.
Ziegler D, Mayer P and Gries FA Evaluation of thermal, pain and vibration sensation thresholds in newly diagnosed type 1 diabetic patients. J. Neural Neurosurg. Psychiatry1988; 51: 1420-1424.
Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994; 344: 796-798.
Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes1991; 40: 405-412.
Cameron NE and Cotter MA, The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes/Metab. Rev 1994; 10: 189-224.
Russell JW, Golovoy D, Vincent AM, Mahendru P, Olzmann JA, Mentzer A and Feldman EL, High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J 2002, 16: 1738 -1748.
Polydefkis M, Griffin JW and McArthur J. New insights into diabetic polyneuropathy. J. Am. Med. Assoc2003; 290: 1371-1376.
Suzuki YJ, Tsuchiya M and Packer L. Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species. Free. Radic. Res. Commun 1991; 15: 255 -263.
Nagamatsu, M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA,.Tritschler H and Low PA,. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160 -1167.
Vinik, AL, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB and Colen LB. Diabetic neuropathies. Diabetes Care 1992; 15: 1926-1975.
Nickander, KK, McPhee BR, Low PA and Tritschler H. Alpha-lipoic acid: Antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radical Biol. Med 1996; 21: 631-639.
Judzewitsch, RG, Jaspan JB, Polonsky KS, Weinberg CR. and Halter JB et al. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N. Engl. J. Med. 1983; 309: 119-125.
Chiarelli, F, Santilli F and Mohn A. Role of growth factors in the development of diabetic complications. Hormone Res2000; 53: 53-76.
Apfel SC Nerve regeneration in diabetic neuropathy. Diabetes Obesity Metab 1999; 1: 3-11.
Packer L. The role of anti-oxidative treatment in diabetes mellitus. Diabetologia1993; 36: 1212-1213.
Kohara, N, Kimura J, Kaji R, Goto Y, Ishii J, Takiguchi M and Nakai M. F-wave latency serves as the most reproducible measure in nerve conduction studies of diabetic polyneuropathy: Multicentre analysis in healthy subjects and patients with diabetic polyneuropathy. Diabetologia 2000; 43: 915-921.
Obrosova, IG, Douglas AG and Hans-Jochen L. Antioxidative Defense in Diabetic Peripheral Nerve: Effects of DL-α-lipoic Acid, Aldose Reductase Inhibitor and Sorbitol Dehydrogenase Inhibitor. In: Antioxidant in Diabetes Management, Rosen, P. (Ed.). Marcel Dekker Inc., New York, USA, 2000. p. 93-110.